

Date: May 19, 2026

To,  
BSE Limited,  
20th Floor, P.J. Towers,  
Dalal Street,  
Mumbai - 400001.  
BSE Scrip Code: 544449

National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai – 400 051  
NSE Scrip Symbol: ANTHEM

**Subject:** Outcome of the Board Meeting held on Tuesday, May 19, 2026

Dear Sir/Ma'am

Pursuant to Regulation 30 and 33 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (**Listing Regulations**), we hereby inform you that the Board of Directors of Anthem Biosciences Limited (*formerly known as Anthem Biosciences Private Limited*) (**Company**) at its meeting held on Tuesday, May 19, 2026 which commenced at 02:00 p.m. and concluded at 4:00 p.m. have inter-alia, considered and approved the following matters:

### **1. Audited Financial Results**

The Board of Directors (**Board**) approved the Audited Standalone and Consolidated Financial Results of the Company prepared as per Indian Accounting Standard (Ind-AS) along with the Auditor's reports thereon for the quarter and year ended March 31, 2026. A Copy of the financials results along with the Auditor's Report were duly reviewed and recommended by Audit Committee at its meeting held on the same day to the Board.

A copy of the said Audited Standalone and Consolidated Financial Results along with Auditor's Report are enclosed herewith and the extract of the results will be published in the newspapers as required under Regulation 47(1) of SEBI Listing Regulations.

The Declaration issued by Mr. Mohammed Gawir Baig, Chief Financial Officer of the Company, under Regulation 33(3)(d) of the SEBI Listing Regulations, regarding the Audit Report with unmodified opinion on the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026, issued by M/s. K. P. Rao & Co., Chartered Accountants (Firm Registration No. 003135S), Statutory Auditors of the Company, is enclosed herewith as **Annexure A**.

## 2. Final Dividend

The Board recommended a final dividend of INR 2.00 per equity share of face value of INR 2.00 each for the Financial Year ended March 31, 2026, subject to the Shareholders approval at the ensuing Annual General Meeting of the Company. Accordingly, the said dividend, if approved, by the Shareholders at the ensuing Annual General Meeting of the Company, will be paid within 30 days from the date of Annual General Meeting, subject to deduction of tax at source.

The record date for the purpose of payment of final dividend is Friday, June 26, 2026.

## 3. Annual General Meeting

The Board approved convening the 20<sup>th</sup> Annual General Meeting (*AGM*) of the Company on Wednesday July 22, 2026. The Copy of the 20<sup>th</sup> AGM Notice will be sent in due course.

## 4. Allotment of Equity Shares pursuant to Anthem Employee Stock Option Plan 2024

The Board approved allotment of 14,81,250 Equity Shares of face value of INR 2.00 each to the eligible employees of the Company upon exercise of the Options vested with them under the Anthem Employee Stock Option Plan 2024.

Consequent to this allotment, the paid-up equity share capital of the Company stands increased from *INR 1,12,34,27,702/-* (consisting of *56,17,13,851* equity shares of face value of INR 2.00 each) to *INR 1,12,63,90,202/-* (consisting of *56,31,95,101* equity shares of face value of INR 2.00 each).

The details as required under the Regulation 10(c) SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 are enclosed herewith as *Annexure B*

## 5. Re-appointment of Internal Auditors

The Board approved the re-appointment of M/s. BPU & Co., Chartered Accountants (Firm Registration Number 001765S) as the Internal Auditor of the Company as recommended by the Audit Committee, for conducting internal audit of the Company for the financial year 2026-2027.

The details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed herewith as *Annexure C*.

## 6. Recommend the continuation of Mr. Ravikant Uppal as Non-Executive Independent Director of the Company

The Board approved and recommended the continuation of Mr. Ravikant Uppal as a Non-Executive Independent Director of the Company, upon his attaining the age of 75 years on May 09, 2027, pursuant to Regulation 17(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, subject to the approval of the Shareholders at the ensuing Annual General Meeting of the Company.

**7. Recommend the re-appointment of Mr. Ravindra Chandrappa, Whole Time Director of the Company**

The Board approved and recommended the re-appointment of Mr. Ravindra Chandrappa, Whole Time Director, who retires by rotation and, being eligible, has offered himself for re-appointment, pursuant to section 152(6) of the Companies Act, 2013, subject to approval of the Shareholders at the ensuing Annual General Meeting of the Company.

The detailed disclosures for the aforesaid appointments as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, enclosed herewith as **Annexure D**.

The above intimation is also available on the Company's website at <https://anthembio.com/investors/>.

We request you to kindly take the same on record.

Thanking you,

Yours truly,

For Anthem Biosciences Limited

*(Formerly known as Anthem Biosciences Private Limited)*

**DIVYA**  
**PRASAD**

Digitally signed by  
DIVYA PRASAD  
Date: 2026.05.19  
18:44:35 +05'30'

**Divya Prasad**

**Company Secretary & Compliance Officer**

**Membership No: A41438**

K. P. RAO  
H.N. ANIL  
MOHAN R LAVI

K. VISWANATH  
S. PRASHANTH  
P. RAVINDRANATH

Phone : 080 - 25587385 / 25586814  
Fax : 080 - 25594661  
E-mail : info@kpao.co.in

## INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Anthem Biosciences Limited

Report on the Audit of Standalone Financial Results

### Opinion

We have audited the accompanying Standalone Annual Financial Results ("the Statement") of **Anthem Biosciences Limited** (hereinafter referred to as the "Company") for the year ended 31<sup>st</sup> March 2026, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India ("Listing Obligations and Disclosure Requirements") Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us the aforesaid Statement:

- i) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of Standalone net profit and other comprehensive income and other financial information of the Company for the year ended 31<sup>st</sup> March 2026.

### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") as specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Standalone financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the Statement.

### Responsibilities of management and those charged with governance for the statement


The Statement has been prepared on the basis of the Standalone annual financial statements and has been approved by the Board of Directors. The Company's Board of Directors are responsible for the preparation and presentation of the Statement that gives a true and fair view of the Standalone net profit after tax and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting

#### Branches

Hyderabad : 3rd Floor, D1, 6-3-652, Kautilya, Somajiguda, Hyderabad - 500 082. Ph.: 040-23322310

Mysore : 74, 2nd Main, First Stage, Vijayanagar, Mysore - 570 017. Ph.: 0821-4271908

Chennai : Flat 2-A, Second Floor, Shruthi 3/7, 8th Cross Street, Shastrinagar, Adayar, Chennai - 600 020. Ph.: 044- 24903137 / 45511564



## CHARTERED ACCOUNTANTS

Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and compliance with Regulation 33 of the Listing Regulations. The Management and Board of Directors of the company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies ; making judgments and estimates that are reasonable and prudent ; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and are free from material misstatement , whether due to fraud or error.

In preparing the Statement, the Board of Directors of the company are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the company or to cease operations or has no realistic alternative but to do so.


The Board of Directors of the company is responsible for overseeing the financial reporting process.

### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the Statement made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the



going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in *our* auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure, and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with Those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide Those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### Other Matters

The Statement includes the results for the quarter ended 31<sup>st</sup> March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subjected to limited review by us. Our report on the Statement is not modified in respect of this matter.

For K P Rao & Co

Chartered Accountants

Firm Registration No. 003135S




Mohan R Lavi

Partner

Membership No. 029340

UDIN: 26029340YPVNAX7062



Place: Bangalore

Date: May 19, 2026

**ANTHEM BIOSCIENCES LIMITED**  
CORPORATE IDENTITY NUMBER: L24233KA2006PLC039703

REGISTERED AND CORPORATE OFFICE: NO 49, F1&F2, CANARA BANK ROAD, BOMMASANDRA INDUSTRIAL AREA, PHASE-I, BOMMASANDRA, BANGALORE-560099,  
KARNATAKA INDIA.

Email : investors abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com

**STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE YEAR ENDED 31 MARCH 2026 AND  
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31 MARCH 2026**

Particulars	(₹.in Millions)				
	Quarter ended			Year End	Year End
	31/03/2026	31/12/2025	31/03/2025	31/03/2026	31/03/2025
	Unaudited (Note 4)	Unaudited	Unaudited (Note 4)	Audited	Audited
<b>Income:</b>					
Revenue from operations	5,825.01	4,165.75	4,789.84	20,893.12	18,406.49
Other income	606.25	399.22	378.19	1,820.75	1,094.40
<b>Total Income</b>	<b>6,431.26</b>	<b>4,564.98</b>	<b>5,168.03</b>	<b>22,713.87</b>	<b>19,500.89</b>
<b>Expenses:</b>					
Cost of materials consumed	1,500.74	1,805.71	1,822.68	6,967.51	8,280.79
Changes in inventories of finished goods, work-in-progress and stock in trade	502.54	(423.33)	(67.18)	986.91	(867.05)
Employee benefit expenses	667.25	654.71	564.26	2,639.24	2,521.67
Finance cost	15.83	11.27	21.03	65.47	90.89
Depreciation and amortisation expense	262.84	267.48	209.89	995.65	779.37
Other expenses	484.57	498.20	488.97	1,788.25	1,580.97
<b>Total Expenses</b>	<b>3,433.76</b>	<b>2,814.04</b>	<b>3,039.64</b>	<b>13,443.04</b>	<b>12,386.66</b>
<b>Profit before exceptional items and tax</b>	<b>2,997.50</b>	<b>1,750.94</b>	<b>2,128.39</b>	<b>9,270.84</b>	<b>7,114.23</b>
Exceptional items	(9.71)	249.84	-	240.13	-
<b>Profit before tax</b>	<b>3,007.21</b>	<b>1,501.10</b>	<b>2,128.39</b>	<b>9,030.70</b>	<b>7,114.23</b>
<b>Tax expense</b>					
Current tax	897.06	377.80	565.43	2,413.05	1,820.27
Deferred tax	(6.50)	2.05	337.32	(87.99)	232.08
<b>Total tax expenses</b>	<b>890.56</b>	<b>379.84</b>	<b>902.76</b>	<b>2,325.06</b>	<b>2,052.36</b>
<b>Profit for the Period/Year</b>	<b>2,116.65</b>	<b>1,121.25</b>	<b>1,225.63</b>	<b>6,705.64</b>	<b>5,061.88</b>
<b>Other comprehensive income</b>					
Other comprehensive income/(loss) not to be reclassified to profit or loss in subsequent period	(10.93)	(9.80)	2.06	(20.04)	(5.30)
Income tax on above	2.75	2.47	(0.52)	5.04	1.33
<b>Other comprehensive income/(loss) for the period/year</b>	<b>(8.18)</b>	<b>(7.33)</b>	<b>1.54</b>	<b>(15.00)</b>	<b>(3.96)</b>
<b>Total comprehensive income for the period/year</b>	<b>2,108.47</b>	<b>1,113.92</b>	<b>1,227.17</b>	<b>6,690.64</b>	<b>5,057.91</b>
<b>Paid-up equity share capital (face value of Rs.2 each)</b>	<b>1,123.43</b>	<b>1,123.22</b>	<b>1,118.15</b>	<b>1,123.43</b>	<b>1,118.15</b>
<b>Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity'</b>				<b>30,723.58</b>	<b>23,613.97</b>
<b>Earnings per equity share</b>	Not annualised	Not annualised	Not annualised	Annualised	Annualised
a)Basic	3.77	2.00	2.19	11.95	9.05
b)Diluted	3.73	1.98	2.18	11.82	9.01

See accompanying notes to financial results



**ANTHEM BIOSCIENCES LIMITED**

CORPORATE IDENTITY NUMBER: L24233KA2006PLC039703

REGISTERED AND CORPORATE OFFICE: NO 49, F1&F2, CANARA BANK ROAD, BOMMASANDRA INDUSTRIAL AREA, PHASE-I, BOMMASANDRA, BANGALORE-560099, KARNATAKA INDIA.

Email : investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com

**STATEMENT OF AUDITED STANDALONE ASSET & LIABILITY FOR YEAR ENDED MARCH 31, 2026**

Particulars	(₹.in Millions)	
	Audited As at 31.03.2026	Audited As at 31.03.2025
<b>I ASSETS</b>		
1) <b>Non-current assets</b>		
a) Property, plant and equipment	6,096.00	6,155.39
b) Right of use assets	25.26	47.91
c) Capital work-in-progress	835.22	579.42
d) Intangible assets	4.36	37.26
e) <b>Financial Assets</b>		
i) Investment	7,175.44	2,209.29
ii) Trade receivables	44.56	43.20
iii) Loans & Advances	2,027.33	3,327.35
iv) Other Financial Asset	1,651.97	1,556.19
f) Deferred tax assets	276.38	183.35
g) Non-Current tax assets (net)	128.57	14.01
h) Other non-current assets	159.35	47.06
<b>Total Non-current assets</b>	<b>18,424.43</b>	<b>14,200.42</b>
2) <b>Current assets</b>		
a) Inventories	1,191.39	3,386.03
b) <b>Financial assets</b>		
i) Investment	6,625.65	3,122.91
ii) Trade receivables	5,729.33	4,479.10
iii) Cash and cash equivalents	2,678.82	1,654.15
iv) Bank balances, other than (iii) above	19.71	8.39
v) Other Financial Asset	2.96	4.12
c) Other current assets	636.16	1,500.53
<b>Total Current assets</b>	<b>16,884.03</b>	<b>14,155.22</b>
<b>TOTAL ASSETS</b>	<b>35,308.46</b>	<b>28,355.64</b>
<b>II EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
a) Equity share capital	1,123.43	1,118.15
b) Other equity	30,723.58	23,613.97
<b>Total Equity</b>	<b>31,847.01</b>	<b>24,732.12</b>
<b>Liabilities</b>		
1) <b>Non-current liabilities</b>		
a) <b>Financial liabilities</b>		
i) Borrowings	281.98	470.28
ii) Lease liabilities	8.83	28.56
iii) Other financial liabilities	153.78	131.53
b) Provisions	155.19	72.04
c) Other non-current liabilities	7.00	9.34
<b>Total non-current liabilities</b>	<b>606.78</b>	<b>711.76</b>
2) <b>Current liabilities</b>		
a) <b>Financial liabilities</b>		
i) Borrowings	189.74	619.26
ii) Lease liabilities	19.73	15.06
iii) <b>Trade Payables</b>		
(a) Dues of Micro enterprises & small enterprises	64.05	100.11
(b) Dues to other than Micro enterprises & small enterprises	639.39	1,000.83
iv) Other financial liabilities	39.42	58.40
b) Other current liabilities	1,324.99	849.63
c) Provisions	204.30	38.18
d) Current Tax Liabilities (net)	373.05	230.27
<b>Total current liabilities</b>	<b>2,854.67</b>	<b>2,911.76</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>35,308.46</b>	<b>28,355.64</b>



**STANDALONE STATEMENT OF CASH FLOWS FOR YEAR ENDED MARCH 31, 2026**

Particulars	(₹.in Millions)	
	Year ended 31 <sup>st</sup> March 2026	Year ended 31 <sup>st</sup> March 2025
	Audited	Audited
<b>A. Cash Flow from operating activities:</b>		
Profit before tax	9,030.70	7,114.23
<b>Adjustment:</b>		
Depreciation/ Amortisation	995.65	779.37
Gain on investment carried at Fair Value through Profit or Loss(FVTPL)	23.43	1.00
Provision for gratuity and leave encashment	249.28	11.40
Bad Debts written off	0.32	0.24
Provision for doubtful debts	5.41	20.20
Unrealized foreign exchange (gain)/loss	(145.47)	73.84
Interest and finance charges	65.47	90.89
Interest from deposits & advances	(1,056.90)	(884.11)
Capital gain from Mutual Funds	(72.32)	(74.78)
Employee share based payment	153.40	343.46
(Profit)/Loss on sale of asset	0.28	4.37
<b>Operating Profit before Working Capital Changes</b>	<b>9,249.26</b>	<b>7,480.12</b>
<b>Adjustment for changes in working capital:</b>		
(Increase)/Decrease in Other financial Assets	(94.62)	(1,506.21)
(Increase)/Decrease in Other Current Assets	1,019.64	(490.44)
(Increase)/Decrease in Other non-current Assets	(226.85)	(19.35)
Increase/(Decrease) in Current financial liabilities	(18.99)	(0.82)
(Increase)/Decrease in Trade and other receivables	(1,109.14)	336.87
(Increase)/Decrease in Inventories	2,194.64	(1,272.94)
Increase/(Decrease) in Trade payables and other liabilities	(397.50)	96.88
Increase/(Decrease) in Other current liabilities	337.75	(4.05)
Increase/(Decrease) in Provisions	(20.04)	(25.50)
<b>Cash generated from operating activities</b>	<b>10,934.15</b>	<b>4,594.58</b>
Income taxes paid, net	(2,040.00)	(1,590.00)
<b>Net cash generated from operating activities</b>	<b>8,894.15</b>	<b>3,004.58</b>
<b>B. Cash Flow from Investing Activities:</b>		
Purchase of Property, Plant & Equipment and other Intangible assets (Including Capital work in progress Capital advance, capital creditors & Right of	(1,399.79)	(1,317.86)
Proceeds from sale of Property, Plant and Equipment	37.72	22.75
Investment in equity shares of subsidiaries	(2,755.19)	(1,000.00)
Proceeds/(Investment) in other entities	15.54	(43.75)
Proceeds/(Investment) in mutual funds and corporate bonds	(5,747.48)	428.29
Interest income received	1,056.90	884.11
Capital gain from Mutual Funds	72.32	74.78
Receipt/(payment) of loans and advances to related party	1,300.02	(1,540.01)
<b>Net cash used in Investing activities</b>	<b>(7,419.97)</b>	<b>(2,491.69)</b>
<b>C. Cash flow from Financing activities:</b>		
Proceeds from issue of equity shares	265.65	-
Repayment of non-current borrowings	(188.30)	(189.28)
Other Non-Current liabilities	0.17	(1.20)
Repayment of interest portion of lease liabilities	(2.93)	(4.20)
Repayment of principal portion of lease liabilities	(15.06)	(16.29)
Proceeds/(repayment) of short term borrowings	(429.53)	(389.41)
Interest and finance charges	(65.47)	(84.33)
<b>Net cash (Used)/ Generated in Financing Activities</b>	<b>(435.47)</b>	<b>(684.70)</b>
<b>Net change in Cash and Cash Equivalents (A+B+C)</b>	<b>1,038.71</b>	<b>(171.81)</b>
<b>D. Effect of exchange differences on cash and cash equivalents held in foreign currency</b>	<b>(2.71)</b>	<b>(4.13)</b>
Cash and Cash Equivalents (beginning of the year)	1,662.54	1,838.47
<b>Cash and Cash Equivalents (ending period)</b>	<b>2,698.53</b>	<b>1,662.54</b>
Cash on hand	0.00	0.05
Balances with banks		
In current accounts	115.39	68.13
In EEFC accounts	12.98	42.42
In deposits accounts	2,570.17	1,551.94



**Notes to standalone financial statements.**

1 These audited standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 ("the Regulations").

2 The above statement of audited standalone financial results ("the Statements") of the Company for the year ended 31st March 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on May 19, 2026. The Statutory Auditor have expressed an unmodified opinion.

The Company has completed its IPO of Offer for Sale equity shares of face value of Rs. 2/- each at an issue price of Rs. 570/- per equity share, comprising 3 offer for sale of 59,575,319 shares by selling share holders. The equity shares of the company were listed on NSE Limited and BSE Limited on July 21, 2025

On July 21, 2025 the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE). Accordingly, comparative numbers for the quarter ended March 31, 2025 were not subjected to a review by statutory auditors of the Company and are prepared by the management of the Company, reviewed by the Audit Committee and approved by the Board of Directors of the Company. The figures 4 for the current quarter ended 31 March 2026 is the balancing figures between the audited figures in respect of the full financial year ended 31 March 2026 and published year to date figures for the nine months ended 31 December 2025 which were subjected to limited review by the statutory auditors of the Company.

5 During the year, the company has allotted 2,532,951 nos of fully paid up equity shares of Rs.2 each under "ESOP Scheme 2024" on approval accorded by the Board of Directors of the company at their meetings held on June 11, 2025 and 103,800 nos of fully paid up equity shares of Rs.2 each under "ESOP Scheme 2024" on approval accorded by the Board of Directors of the company at their meetings held on February 05, 2026 respectively.

On November 21, 2025, the Government of India notified four new Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment has published draft Central Rules and FAQs in this regard. The Company has assessed and made a provision, as an Exceptional Item consistent with the guidance provided by the Institute of Chartered Accountants of India, in the financial results for the quarter and year ended March 31, 2026.

6 During the quarter ended 31 March 2026, the management reassessed the impact of this change based on the revised remuneration structure, which resulted in a credit of Rs. 9.71 million in the Standalone financial results. Accordingly, for the year ended 31 March 2026, the net expense recognized in "Exceptional Item" amounts to Rs. 240.13 million in the Standalone financial results.

In case of any further clarification from the Government on other aspects of the Labour Codes, the Company will evaluate and account for differential impact, if any, in subsequent periods.

7 Prior period/year figures have been reclassified wherever required to confirm to the classification of the current period/year.

**For and on behalf of the board of directors of**

**Anthem Biosciences Limited**

CIN:L24233KA2006PLC039703

AJAY  
BHARDWAJ  
Digitally signed by  
AJAY BHARDWAJ  
Date: 2026.05.19  
18:15:49 +05'30'

Ajay Bhardwaj  
Managing Director  
DIN: 00333704

Place: Bangalore  
Date: May 19, 2026



K. P. RAO  
H.N. ANIL  
MOHAN R LAVI

K. VISWANATH  
S. PRASHANTH  
P. RAVINDRANATH

Phone : 080 - 25587385 / 25586814  
Fax : 080 - 25594661  
E-mail : info@kprao.co.in

## INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Anthem Biosciences Limited

### Report on the Audit of Consolidated Financial Results

#### Opinion

We have audited the accompanying consolidated annual financial results (" the Statement") of **Anthem Biosciences Limited** ( the " Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group") for the year ended 31<sup>st</sup> March 2026 ('Consolidated annual financial results'), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i) includes the financial results of one Subsidiary Company Neoanthem Lifesciences Private Limited (Wholly owned Subsidiary)
- ii) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations and
- iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the consolidated net on and other comprehensive income and other financial information of the Group for the year ended 31<sup>st</sup> March 2026.

#### Basis for Opinion


We conducted our audit in accordance with the Standards on Auditing ("SAs") as specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results section of our report. We are independent of the Group and its subsidiaries, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Statement under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us are sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

#### Branches

Hyderabad : 3rd Floor, D1, 6-3-652, Kautilya, Somajiguda, Hyderabad - 500 082. Ph.: 040-23322310

Mysore : 74, 2nd Main, First Stage, Vijayanagar, Mysore - 570 017. Ph.: 0821-4271908

Chennai : Flat 2-A, Second Floor, Shruthi 3/7, 8th Cross Street, Shastrinagar, Adayar, Chennai - 600 020. Ph.: 044- 24903137 / 45511564



**Responsibilities of management and those charged with governance for the statement**

The Statement, which is the responsibility of the Holding Company's management and has been approved by the Holding Company's Board of Directors have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of the Statement that gives a true and fair view of the consolidated net profit/loss and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies ; making judgments and estimates that are reasonable and prudent ; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement , whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations or has no realistic alternative but to do so.


The respective Board of Directors of the companies included in the Group is responsible for overseeing the financial reporting process of each company.

**Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from



error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the Statement made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure, and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision, and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision, and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in the "Other Matters" in this audit report.

We communicate with those charged with governance of the Holding Company and its wholly owned subsidiary included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the Circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

#### **Other Matters**

The Statement includes the results of Neoanthem Lifesciences Private Limited (a wholly owned subsidiary).



The Statement includes the audited financial results of one subsidiary, whose results reflect total asset of Rs. 4,712.05 million as at 31st March 2026, total revenue (before consolidation adjustments) of Rs. 713.51 million and total net loss after tax (before consolidation adjustments) of Rs. 787.45 million and total comprehensive loss (net) of Rs. (788.10) million for the year ended 31st March 2026, as considered in the Statement, which have been audited by us.

The Statement includes the results for the quarter ended 31<sup>st</sup> March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subjected to limited review by us. Our report on the Statement is not modified in respect of this matter.


For K P Rao & Co  
Chartered Accountants  
Firm Registration No. 003135S



Mohan R Lavi  
Partner

Membership No. 029340

UDIN: 26029340CB0V0Y5797



Place: Bangalore  
Date: May 19, 2026

**ANTHEM BIOSCIENCES LIMITED**  
CORPORATE IDENTITY NUMBER: L24233KA2006PLC039703

REGISTERED AND CORPORATE OFFICE: NO 49, F1&F2, CANARA BANK ROAD, BOMMASANDRA INDUSTRIAL AREA, PHASE-I, BOMMASANDRA, BANGALORE-560099  
KARNATAKA INDIA.

Email : investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com

**STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED 31 MARCH 2026 AND  
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 31 MARCH 2026**

Particulars	Quarter ended			Year End	Year End
	31/03/2026	31/12/2025	31/03/2025	31/03/2026	31/03/2025
	Unaudited (Note 4)	Unaudited	Unaudited (Note 4)	Audited	Audited
<b>Income:</b>					
Revenue from operations	6,109.43	4,231.53	4,831.97	21,243.33	18,445.53
Other income	512.12	335.30	140.62	1,557.83	857.32
<b>Total income</b>	<b>6,621.56</b>	<b>4,566.83</b>	<b>4,972.59</b>	<b>22,801.16</b>	<b>19,302.85</b>
<b>Expenses:</b>					
Cost of materials consumed	1,652.03	1,849.22	1,835.64	7,135.92	8,306.17
Changes in inventories of finished goods, work-in-progress and stock in trade	502.54	(423.33)	(67.18)	986.91	(867.05)
Employee benefit expenses	724.77	704.79	597.78	2,827.05	2,604.94
Finance cost	19.00	3.52	5.21	68.94	103.29
Depreciation and amortisation expense	395.91	345.33	304.22	1,340.70	893.71
Other expenses	557.94	528.85	513.80	1,955.33	1,693.11
<b>Total expenses</b>	<b>3,852.19</b>	<b>3,008.39</b>	<b>3,189.47</b>	<b>14,314.85</b>	<b>12,734.17</b>
<b>Profit before exceptional items and tax</b>	<b>2,769.36</b>	<b>1,558.44</b>	<b>1,783.11</b>	<b>8,486.31</b>	<b>6,568.68</b>
Exceptional items	9.80	253.71	-	243.91	-
Share of Profit of Joint Venture/Associate	-	-	-	-	-
<b>Profit before tax</b>	<b>2,779.16</b>	<b>1,304.74</b>	<b>1,783.11</b>	<b>8,242.40</b>	<b>6,568.68</b>
<b>Tax expense</b>					
Current tax	897.06	377.80	615.84	2,413.05	1,820.27
Deferred tax	(15.47)	(1.23)	341.05	(88.58)	235.81
<b>Total tax expenses</b>	<b>881.58</b>	<b>376.57</b>	<b>956.89</b>	<b>2,324.47</b>	<b>2,056.08</b>
<b>Profit for the Period/Year</b>	<b>1,897.58</b>	<b>928.17</b>	<b>826.22</b>	<b>5,917.92</b>	<b>4,512.60</b>
<b>Other comprehensive income</b>					
Other comprehensive income/(loss) not to be reclassified to profit or loss in subsequent period	(10.30)	(10.64)	2.06	(20.83)	(5.30)
Income tax on above	2.64	2.85	(0.52)	5.18	1.33
Share of OCI of Joint Venture/Associate	-	-	-	-	-
<b>Other comprehensive income/(loss) for the period/year</b>	<b>(7.66)</b>	<b>(7.80)</b>	<b>1.54</b>	<b>(15.65)</b>	<b>(3.96)</b>
<b>Total comprehensive income for the period/year</b>	<b>1,889.92</b>	<b>920.37</b>	<b>827.76</b>	<b>5,902.28</b>	<b>4,508.64</b>
<b>Paid-up equity share capital (face value of Rs.2 each)</b>	<b>1,123.43</b>	<b>1,123.22</b>	<b>1,118.15</b>	<b>1,123.43</b>	<b>1,118.15</b>
<b>Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity'</b>				<b>29,301.73</b>	<b>22,980.48</b>
Non-controlling interests					
<b>Earnings per share</b>	Not annualised	Not annualised	Not annualised	Annualised	Annualised
a) Basic	3.38	1.65	1.48	10.55	8.07
b) Diluted	3.34	1.64	1.47	10.43	8.04

See accompanying notes to financial results



**ANTHEM BIOSCIENCES LIMITED**

CORPORATE IDENTITY NUMBER: L24233KA2006PLC039703

REGISTERED AND CORPORATE OFFICE: NO 49, F1&F2, CANARA BANK ROAD, BOMMASANDRA INDUSTRIAL AREA, PHASE-I, BOMMASANDRA, BANGALORE-560099. KARNATAKA INDIA.

Email : investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com

**STATEMENT OF AUDITED CONSOLIDATED ASSET & LIABILITY FOR YEAR ENDED MARCH 31, 2026**

Particulars	₹.in Millions	
	Audited As at 31.03.2026	Audited As at 31.03.2025
<b>I ASSETS</b>		
1) Non-current assets		
a) Property, plant and equipment	7,802.63	6,964.42
b) Right of use assets	25.26	47.91
c) Capital work-in-progress	2,643.46	2,968.81
d) Intangible assets	4.41	38.71
e) Financial Assets		
i) Investment	3,418.75	1,207.79
ii) Trade receivables	31.08	31.12
iii) Loans & Advances	73.06	33.18
iv) Other Financial Asset	1,662.54	1,566.61
f) Deferred tax assets	273.22	179.47
g) Non-Current tax assets (net)	128.57	14.01
h) Other non-current assets	198.48	142.10
<b>Total Non-current assets</b>	<b>16,261.46</b>	<b>13,194.13</b>
2) Current assets		
a) Inventories	1,245.16	3,404.34
b) Financial assets		
i) Investment	6,655.87	3,122.91
ii) Trade receivables	5,905.88	4,503.96
iii) Cash and cash equivalents	2,729.09	1,714.45
iv) Bank balances, other than (iii) above	19.71	8.39
v) Other Financial Asset	2.96	4.26
c) Other current assets	1,472.78	2,123.39
<b>Total Current assets</b>	<b>18,031.45</b>	<b>14,881.70</b>
<b>TOTAL ASSETS</b>	<b>34,292.90</b>	<b>28,075.83</b>
<b>II EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
a) Equity Share capital	1,123.43	1,118.15
b) Other equity	29,301.73	22,980.48
<b>Total Equity</b>	<b>30,425.16</b>	<b>24,098.64</b>
<b>Liabilities</b>		
1) Non-current liabilities		
a) Financial liabilities		
i) Borrowings	277.34	470.28
ii) Lease liabilities	8.83	28.56
iii) Other financial liabilities	153.78	131.53
b) Provisions	163.66	75.15
c) Other non-current liabilities	7.00	9.34
<b>Total non-current liabilities</b>	<b>610.61</b>	<b>714.87</b>
2) Current liabilities		
a) Financial liabilities		
i) Borrowings	233.34	619.26
ii) Lease liabilities	19.73	15.06
iii) Trade Payables		
(a) Dues of Micro enterprises & small enterprises	89.08	106.01
(b) Dues to other than Micro enterprises & small enterprises	663.09	994.86
iv) Other financial liabilities	39.42	58.40
b) Other current liabilities	1,629.77	1,199.57
c) Provisions	209.66	38.89
d) Current Tax Liabilities (net)	373.05	230.27
<b>Total current liabilities</b>	<b>3,257.14</b>	<b>3,262.33</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>34,292.90</b>	<b>28,075.83</b>



**CONSOLIDATED STATEMENT OF CASH FLOWS FOR YEAR ENDED MARCH 31, 2026**

Particulars	(Rs. in million)	
	Year ended 31 <sup>st</sup> March 2026	Year ended 31 <sup>st</sup> March 2025
	(Audited)	(Audited)
<b>A. Cash Flow from Operating Activities</b>		
Profit before tax	8,242.40	6,568.68
<b>Adjustment:</b>		
Depreciation/ Amortisation	1,340.70	893.71
Gain on investment carried at Fair Value through Profit or Loss(FVTPL)	23.56	1.00
Provision for gratuity and leave encashment	259.29	15.22
Bad Debts written off	0.32	0.24
Provision for doubtful debts	5.41	20.20
Unrealized foreign exchange (gain)/loss	(143.69)	74.04
Interest and finance charges	68.94	103.29
Interest from deposits & advances	(792.70)	(647.00)
Capital gain from mutual funds	(72.42)	(74.78)
Employee share based payment	158.59	343.46
(Profit)/Loss on sale of asset	0.28	4.37
<b>Operating Profit before Working Capital Changes</b>	<b>9,090.67</b>	<b>7,302.43</b>
<b>Adjustment for changes in working capital:</b>		
(Increase)/Decrease in Other financial Assets	(94.62)	(1,506.60)
(Increase)/Decrease in Other Current Assets	650.62	(838.46)
(Increase)/Decrease in Other non-current Assets	(70.95)	55.99
Increase/(Decrease) in Current financial liabilities	(18.99)	(0.82)
(Increase)/Decrease in Trade and other receivables	(1,261.20)	330.23
(Increase)/Decrease in Inventories	2,159.18	(1,290.87)
Increase/(Decrease) in Trade payables and other liabilities	(348.70)	93.75
Increase/(Decrease) in Other current liabilities	399.68	175.35
Increase/(Decrease) in Provisions	(20.83)	(25.50)
<b>Cash generated from operating activities</b>	<b>10,484.85</b>	<b>4,295.51</b>
Income taxes paid, net	(2,040.00)	(1,590.00)
<b>Net cash generated from operating activities</b>	<b>8,444.85</b>	<b>2,705.51</b>
<b>B. Cash Flow from Investing Activities:</b>		
Purchase of Property, Plant & Equipment and other Intangible assets (Including Capital work in progress Capital advance, capital creditors & Right of Use Assets)	(2,111.69)	(2,612.08)
Proceeds from sale of Property, Plant and Equipment	37.72	22.75
Investment in equity shares of subsidiaries		
Proceeds/(Investment) in other entities	15.54	(43.75)
Proceeds/(Investment) in mutual funds and corporate bonds	(5,783.02)	428.29
Interest income received	792.70	647.00
Capital gain from Mutual Funds	72.42	74.78
Receipt/(payment) of loans and advances to related party	(39.88)	17.37
<b>Net cash used in Investing activities</b>	<b>(7,016.21)</b>	<b>(1,465.65)</b>
<b>C. Cash flow from Financing activities:</b>		
Proceeds from issue of equity shares	265.65	-
Repayment of non-current borrowings	(192.94)	(648.67)
Other Non-Current liabilities	0.17	(1.20)
Repayment of interest portion of lease liabilities	(2.93)	(4.20)
Repayment of principal portion of lease liabilities	(15.06)	(16.29)
Proceeds/(repayment) of short term borrowings	(385.93)	(589.41)
Interest and finance charges	(68.94)	(96.73)
<b>Net cash (Used)/ Generated in Financing Activities</b>	<b>(399.98)</b>	<b>(1,356.48)</b>
<b>Net change in Cash and Cash Equivalents (A+B+C)</b>	<b>1,028.67</b>	<b>(116.61)</b>
Effect of exchange differences on cash and cash equivalents held in foreign currency	(2.71)	(4.19)
Cash and Cash Equivalents (beginning of the year)	1,722.84	1,843.58
<b>Cash and Cash Equivalents (ending period)</b>	<b>2,748.80</b>	<b>1,722.84</b>
Cash on hand	0.00	0.05
Balances with banks		
In current accounts	156.87	81.21
In EEFC account	12.98	42.42
In deposits accounts	2,578.95	1,599.17



**Notes to consolidated financial statements.**

1 These audited consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 ("the Regulations").

2 The above statement of audited consolidated financial results ("the Statements") of the Company for the year ended 31st March 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 19th May 2026. The Statutory Auditor have expressed an unmodified opinion.

3 The Company has completed its IPO of Offer for Sale of equity shares of face value of Rs. 2/- each at an issue price of Rs. 570/- per equity share, comprising offer for sale of 59,575,319 shares by selling share holders. The equity shares of the company were listed on NSE Limited and BSE Limited on July 21, 2025.

4 On July 21, 2025 the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE). Accordingly, comparative numbers for the quarter ended March 31, 2025 were not subjected to a review by statutory auditors of the Company and are prepared by the management of the Company, reviewed by the Audit Committee and approved by the Board of Directors of the Company. The figures for the current quarter ended 31 March 2026 is the balancing figures between the audited figures in respect of the full financial year ended 31 March 2026 and published year to date figures for the nine months ended 31 December 2025 which were subjected to limited review by the statutory auditors of the Company.

5 During the year, the company has allotted 2,532,951 nos of fully paid up equity shares of Rs.2 each under "ESOP Scheme 2024" on approval accorded by the Board of Directors of the company at their meetings held on June 11, 2025 and 103,800 nos of fully paid up equity shares of Rs.2 each under "ESOP Scheme 2024" on approval accorded by the Board of Directors of the company at their meetings held on February 05, 2026.respectively

6 The consolidated financial statements include the financial results of Anthem Biosciences Limited (Parent Company) and of the following subsidiaries:  
Neonanthem Lifesciences Private limited (wholly owned subsidiary)

7 On November 21, 2025, the Government of India notified four new Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment has published draft Central Rules and FAQs in this regard. The Company has assessed and made a provision, as an Exceptional Item consistent with the guidance provided by the Institute of Chartered Accountants of India, in the financial results for the quarter and period ended December 31, 2025.

During the quarter ended 31 March 2026, the management reassessed the impact of this change based on the revised remuneration structure, which resulted in a credit of Rs. 9.80 million in the Consolidated financial results. Accordingly, for the year ended 31 March 2026, the net expense recognized in "Exceptional Item" amounts to Rs. 243.91 million in the Consolidated financial results.

In case of any further clarification from the Government on other aspects of the Labour Codes, the Company will evaluate and account for differential impact, if any, in subsequent periods.

8 Prior period/year figures have been reclassified wherever required to confirm to the classification of the current period/year.

**For and on behalf of the board of directors of  
Anthem Biosciences Limited**

CIN:L24233KA2006PLC039703

**AJAY**

**BHARDWAJ**

Ajay Bhardwaj  
Managing Director  
DIN: 00333704

Digitally signed by  
AJAY BHARDWAJ  
Date: 2026.05.19  
18:14:32 +05'30'



Place: Bangalore  
Date: May 19, 2026

## Anthem Biosciences Limited

CONSOLIDATED SEGMENT INFORMATION		[Rs. in Mn]			
		Quarter Ended		Year Ended	
		31/03/2026 [Unaudited] Note 4	31/12/2025 [Unaudited] Note 4	31/03/2025 [Unaudited] Note 4	31/03/2026 [Audited]
Sl.No	Particulars				
<b>I</b>	<b>Segment wise revenue and results:</b>				
	<b>Segment revenue:</b>				
	a)CRDMO	5,128.36	3,332.39	3,922.81	17,727.68
	b)Speciality Ingredients	981.07	899.14	909.16	3,515.65
	<b>Total</b>	<b>6,109.43</b>	<b>4,231.53</b>	<b>4,831.97</b>	<b>21,243.33</b>
<b>II</b>	<b>Segmental Results:</b>				
	Gross profits from each segment				
	a)CRDMO	3,438.30	2,347.93	2,608.93	11,329.85
	b)Speciality Ingredients	516.58	457.70	454.58	1,790.65
	<b>Total</b>	<b>3,954.88</b>	<b>2,805.63</b>	<b>3,063.51</b>	<b>13,120.50</b>
	Less: Selling and un-allocable expenditure net of other income	1,175.72	1,500.89	1,280.40	4,878.10
	<b>Total profit before tax:</b>	<b>2,779.16</b>	<b>1,304.74</b>	<b>1,783.11</b>	<b>8,242.40</b>
					<b>6,568.68</b>

The assets and liabilities of the Company are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, assets and liabilities have not been identified to any of the reportable segments.



**Annexure A**

Date: May 19, 2026

To,  
BSE Limited,  
20th Floor, P.J. Towers,  
Dalal Street,  
Mumbai - 400001.  
BSE Scrip Code: 544449

National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai – 400 051  
NSE Scrip Symbol: ANTHEM

Dear Sir/ Madam,

**Subject:** Declaration on Audit Report with unmodified opinion pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015

I, Mr. Mohammed Gawir Baig, Chief Financial Officer of the Company, hereby declare that M/s. K. P. Rao & Co., Chartered Accountants (Firm Registration No. 003135S), statutory auditors of the Company have issued an Audit Report with unmodified opinion on the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026.

This declaration is given in compliance to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2016 and SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016.

Request you to kindly take the above report on record.

Yours truly,  
For Anthem Biosciences Limited  
(Formerly known as Anthem Biosciences Private Limited)

MOHAMMED  
GAWIR BAIG  
Digitally signed by  
MOHAMMED GAWIR  
BAIG  
Date: 2026.05.19 18:45:16  
+05'30'

**Mohammed Gawir Baig**  
**Chief Financial Officer**

## Annexure B

### *Disclosures pursuant to Regulation 10(c) SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021*

<i>Sl No</i>	<i>Particulars</i>	<i>Details</i>
1	Company Name and Address of Registered Office	<i>Anthem Biosciences Limited No. 49, F1 &amp; F2, Canara Bank Road, Bommasandra Industrial Area, Phase I, Bangalore, Karnataka, India, 560099</i>
2	Name of the Stock Exchanges on which the Company's shares are listed	<i>BSE Limited (BSE) National Stock Exchange of India Limited (NSE)</i>
3	Filing date of the statement referred in regulation 10(b) of the SEBI (SBEB) Regulations, with Stock Exchange	<b><u>Approval for 88,76,749 Equity Shares</u></b>  <i>BSE Filing Date: November 03, 2025 BSE Approval Date: November 28, 2025  NSE Filing Date: November 03, 2025 NSE Approval: December 03, 2025</i>
4	Filing Number, if any	<i>BSE: DCS/ESOP/IP/RG/3935/2025-26 NSE: NSE/LIST/51770</i>
5	Title of the Scheme pursuant to which shares are issued	<i>Anthem Employee Stock Option Plan 2024</i>
6	Kind of security to be listed	<i>Equity Shares</i>
7	Par value of the shares	<i>INR 2.00 per share</i>
8	Number of shares issued	<i>14,81,250</i>
9	Share Certificate No., if applicable	<i>Not Applicable</i>
10	Distinctive number of the shares, if applicable	<i>573123552 to 574604801</i>
11	ISIN Number of the shares if issued in Demat	<i>INE0CZ201020</i>
12	Exercise price per share	<i>INR 100.75 per share</i>
13	Premium per share	<i>INR 98.75 per share</i>
14	Total Issued shares after this issue	<i>56,31,95,101</i>

<i>Sl No</i>	<i>Particulars</i>	<i>Details</i>
15	Total Issued share capital after this issue	<i>INR 1,12,63,90,202</i>
16	Details of any lock-in on the shares	<i>Not Applicable</i>
17	Date of expiry of lock-in	<i>Not Applicable</i>
18	Whether shares identical in all respects to existing shares if not, when will they become identical?	<i>All equity shares of the Company allotted pursuant to exercise of stock options shall rank pari-passu with the existing equity shares of the Company.</i>
19	Details of listing fees, if payable	<i>Not Applicable</i>

### Annexure C

*Disclosures pursuant to Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular dated January 30, 2026*

<i>Particulars</i>	<i>Details</i>
Name of Auditors	M/s. BPU & Co., Chartered Accountants ( <i>Internal Auditors</i> )
Reason for change viz. <del>appointment</del> , re-appointment, <del>resignation</del> , <del>removal</del> , <del>death</del> or otherwise;	The Board of Directors of the Company based on the recommendation of the Audit Committee, approved the re-appointment of M/s. BPU & Co., Chartered Accountants as Internal Auditors of the Company for Financial Year 2026-2027
Date of <del>appointment</del> /re appointment	May 19, 2026
Brief Profile	<p>M/s. BPU &amp; Co., Chartered Accountants, is a firm of Chartered Accountants with a team of over 60 professionals having extensive experience across sectors such as information technology, banking, manufacturing, insurance, real estate, retail, and pharmaceutical industries. The firm possesses expertise in internal audit, financial due diligence, valuation, direct and indirect taxation, IND-AS implementation, and regulatory compliances, and has advised several Indian and multinational companies on finance, audit, and business process matters.</p> <p>The firm is led by experienced partners having significant expertise in valuation, internal audit, financial planning, mergers and acquisitions support, indirect taxation and GST advisory, financial controllership, IND-AS implementation, insolvency advisory, and corporate finance functions.</p>

### Annexure D

***Disclosures pursuant to Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular dated January 30, 2026***

<i>Particulars</i>	<i>Mr. Ravikant Uppal</i>	<i>Mr. Ravindra Chandrappa</i>
Reason for change viz. <del>appointment, re-appointment, resignation, removal, death or otherwise;</del>	Continuation of Mr. Ravikant Uppal as the Non-Executive Independent Directors of the Company	Re-appointment of Mr. Ravindra Chandrappa as a Whole Time Director of the Company who retires by rotation and being eligible, has offered himself for re-appointment,
Date of <del>appointment/re</del> appointment	May 09, 2027 subject to approval of Shareholders at ensuing Annual General Meeting	July 22, 2026, subject to approval of Shareholders at ensuing Annual General Meeting
Term of appointment/re appointment	Continuation of Mr. Ravikant Uppal as a Non-Executive Independent Director of the Company pursuant to Regulation 17(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.	Re-appointment as per Section 152(6) of Companies Act 2013
Brief profile	<p>Mr. Ravikant Uppal, aged 74 years, is a Non-Executive Independent Director of the Company. He holds a Bachelor's degree in Mechanical Engineering from the Indian Institute of Technology, Delhi, where he has been honoured as a Distinguished Alumnus, and a Post Graduate Diploma in Business Administration and Management from the Indian Institute of Management, Ahmedabad. He has also completed The Wharton Advanced Management Program from the University of Pennsylvania.</p> <p>Mr. Uppal possesses over four decades of rich experience in business administration and leadership across diverse industries and geographies. He has held several prominent leadership positions, including Managing Director &amp; Group CEO of Jindal Steel &amp; Power</p>	<p>Mr. Ravindra Chandrappa is the Whole Time Director and Chief Operating Officer of the Company. He holds a Bachelor's degree in Chemical Engineering from Bangalore University and has over 25 years of experience in the pharmaceutical and biopharmaceutical industry. He is responsible for leading the end-to-end operations of the Company, including research and development, manufacturing, quality management, and regulatory compliance.</p> <p>He has played a key role in designing and establishing the Company's manufacturing facilities at Bommasandra and Harohalli, including the NeoAnthem manufacturing unit, and is currently leading the development of the Company's fourth manufacturing facility spread</p>

<i>Particulars</i>	<i>Mr. Ravikant Uppal</i>	<i>Mr. Ravindra Chandrappa</i>
	<p>Limited, Whole-time Director on the Board of L&amp;T Group and Managing Director &amp; CEO (Power) at L&amp;T. He has also served in various capacities within the ABB Group and is credited as the Founding Managing Director of Volvo in India.</p> <p>He has extensive international experience across Europe, the Middle East, North Africa, and South East Asia. Mr. Uppal has served on the boards of several companies in India and abroad, including BAE (UK), Actis Private Equity, Riverina Bio Energy (Australia), and TCI Srei Finance. He has also been a member of the Board of Governors of the Indian Institute of Management, Bangalore.</p>	<p>across 30 acres. Under his leadership, the Company has strengthened its advanced technology and manufacturing capabilities through investments in emerging modalities such as RNA interference (RNAi), Antibody-Drug Conjugates (ADCs), peptides, lipids, and oligonucleotides, and by introducing innovative green chemistry technologies including biotransformation and flow chemistry.</p> <p>Mr. Ravindra Chandrappa has also been instrumental in implementing robust quality systems and global cGMP standards across the Company's manufacturing facilities, which are regularly audited and inspected by international regulatory authorities including the USFDA, TGA (Australia), ANVISA (Brazil), PMDA (Japan), and Qualified Persons from Europe. Under his leadership, the Company has successfully implemented digital quality and material management systems, including Veeva Vault Quality and SAP S4/HANA.</p>
Disclosure of relationships between directors	Mr. Ravikant Uppal is not related to any of the Directors or Key Managerial Personnel of the Company.	Mr. Ravindra Chandrappa is not related to any of the Directors or Key Managerial Personnel of the Company.
Information as required under BSE circular no. LIST/COMP/14/2018-19 and NSE circular no. NSE/CML/2018/24, dated June 20, 2018.	Based on information available with the Company, Mr. Ravikant Uppal is not debarred from holding the office of a director by virtue of any SEBI order or any other such authority.	Based on information available with the Company, Mr. Ravindra Chandrappa is not debarred from holding the office of a director by virtue of any SEBI order or any other such authority.